New Depression Study Suggests Arthritis Drug Could Help Where Antidepressants Fail

A pilot clinical trial led by the University of Bristol suggests that targeting the immune system may offer a new treatment option for people with difficult-to-treat depression. The study, published on May 20 in JAMA Psychiatry, tested an immunotherapy drug normally used for inflammatory diseases.

Researchers evaluated whether tocilizumab, a medication commonly prescribed for conditions such as rheumatoid arthritis, could reduce depressive symptoms in adults who had not responded to standard antidepressants. Although the study included only 30 participants, the results suggest potential benefits not only for mood, but also for anxiety, fatigue, and overall quality of life.

Inflammation And Depression Links

Traditional antidepressants mainly target brain chemicals such as serotonin, dopamine, and norepinephrine. However, around one-third of patients experience little or no improvement with these medications, prompting scientists to explore other biological pathways that may contribute to depression.

Increasing evidence points toward inflammation as one possible driver. Studies suggest that about one in three people with depression show elevated inflammatory markers in blood tests. One of the most important inflammatory molecules is interleukin-6, or IL-6, which plays a major role in regulating the body’s immune response and has repeatedly been linked to depressive disorders.

The Bristol-led research team previously used genetic methods known as Mendelian randomization to investigate whether abnormal IL-6 activity could directly contribute to depression rather than simply appear as a consequence of poor mental health. Their earlier findings supported the idea that excessive IL-6 signaling may play a causal role in some forms of depression.

Testing An Arthritis Drug In Depression

To explore this possibility further, researchers conducted a four-week randomized placebo-controlled trial involving people with treatment-resistant depression who also showed signs of low-grade inflammation.

Participants were recruited through the University of Cambridge and NHS services in eastern England.

Fourteen participants received a single infusion of tocilizumab, which blocks the IL-6 receptor, while sixteen participants received a placebo infusion containing saltwater. All volunteers continued their usual medical care while researchers monitored changes in depression severity, anxiety, fatigue, and quality of life over four weeks.

Because the sample size was relatively small, not all differences between groups reached strong statistical significance. Nevertheless, participants who received tocilizumab generally showed greater improvements across multiple measures, with more individuals reporting clinically meaningful relief from symptoms by the end of the trial.

Remission Rates And Potential Significance

By the final assessment, 54 percent of participants treated with tocilizumab met the criteria for remission from depression, compared with 31 percent of those in the placebo group.

Based on these findings, researchers calculated a Number Needed to Treat (NNT) of 5, meaning one additional patient may benefit for every five people treated.

For comparison, commonly prescribed SSRI antidepressants used for moderate-to-severe depression typically have an estimated NNT of around 7. Although direct comparisons between studies have limitations, the findings suggest that immune-targeting approaches could become clinically meaningful for some patients.

Senior author Golam Khandaker described the study as an important step toward developing new treatments for people whose depression does not improve with existing therapies. He emphasized that this is among the first randomized clinical trials of immunotherapy specifically targeting IL-6 signaling in depression.

Toward More Personalized Psychiatry

Lead author Éimear Foley said the findings support a more personalized approach to depression treatment, where therapies are selected based on a patient’s biological profile rather than using the same strategy for everyone.

In this study, only participants with measurable inflammation were included, allowing researchers to focus on people most likely to benefit from immune-targeting treatment.

The work fits into a broader movement in psychiatry and immunology aimed at identifying subgroups of patients whose mental health symptoms may be closely connected to immune dysfunction. In the future, routine blood testing for inflammatory markers could potentially help guide treatment decisions.

One participant said they were pleased to contribute to the research, noting that medical progress depends on volunteers willing to participate in carefully designed clinical trials.

No major safety concerns emerged during the four-week follow-up period, although researchers caution that longer and larger studies are still needed to fully evaluate potential risks.

Next Steps And Broader Context

The researchers stress that these results remain preliminary and should not yet change clinical practice.

Tocilizumab is a powerful immune-modulating medication with known side effects, including increased susceptibility to infections. Any future use for depression would require extensive confirmation in larger clinical trials.

A larger phase III randomized controlled trial is now being planned to test the approach in a much bigger group of patients over a longer period. That study will help determine whether blocking IL-6 signaling could become a recommended treatment option for people with treatment-resistant depression and elevated inflammation.

The pilot study was funded by the Wellcome charity, with additional support from National Institute for Health and Care Research Biomedical Research Centres in Bristol and Cambridge, as well as a grant from the BMA Foundation.

The findings add to a growing body of research exploring whether immune-targeting therapies could eventually become part of mainstream psychiatric treatment.